Fig. 6

TPI1 facilitates breast cancer progression in vivo. A–D MDA-MB-231 luciferase cells stably expressing vector or TPI1 were transplanted into the left axillary regions of nude mice. A group of nude mice were randomly selected to receive MDA-MB-231 cells and treated with LY294002 (75 mg/kg), once every 3 days after primary tumor formation (n = 5/group). Representative bioluminescence photograph and resulting tumors on day 35 (A). Tumor size was measured at 5-day intervals after primary tumor formation (B, left panel). Tumor weight was measured in different groups (B, right panel). Western blot analysis of related markers in mouse tumor tissues (C). β-Actin served as a control. Representative IHC images of mouse tumor tissues with TPI1, CDCA5, p-mTOR, Ki67, E-cadherin and LDHA (D). Scale bar, 20 μm. E–H T47D/vector cells and stable TPI1-knockdown (shTPI1) cells were subcutaneously injected. The photograph of tumors on day 32 (E), tumor growth curves on day 8–32 (F, left panel) and tumor weight (F, right panel) were presented (n = 6/group). Western blot analysis of indicated markers from harvested mouse tumor tissues (G). β-Actin served as a control. Representative IHC images of mouse tumor tissues (H). Scale bar, 20 μm (*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001)